{
  "docId": "019de070-3f4a-73d8-b295-3b15c76ba522",
  "docSlug": "bc1fcb576f82bf5c3541f439604f314c",
  "documentTitle": "Kymera | IPO Presentation Deck | 49 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 49,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a timeline-style header (IND to POC) combined with a table and bulleted list of study parameters.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-3f4a-73d8-b295-3b15c76ba522/34",
  "deckHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522",
  "deckJsonHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522.json",
  "deckAnchorHref": "/decks/019de070-3f4a-73d8-b295-3b15c76ba522#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.15,
        "y": 0.21
      },
      "kind": "diagram",
      "text": "IND to POC timeline",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "210defd4-6fa0-4f35-816b-414b5436053b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.54,
        "x": 0.23,
        "y": 0.43
      },
      "kind": "list",
      "text": "Multi-center dose escalation study (US); B cell lymphomas; Safety, tolerability, PK and PD (POB) and preliminary clinical activity; P1b Expansion cohort in DLBCL (MYD88-mut and -wt) with and without CNS involvement at MTD; Option to amend protocol to explore select combinations; Clinical and biomarker endpoints",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b79fa86e-484b-4b25-a508-7c9d93179f25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.54,
        "x": 0.23,
        "y": 0.28
      },
      "kind": "table",
      "text": "Target Date: H2 2021, Milestones: IND and Study Start; Target Date: H2 2022, Milestones: Clinical POC",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84268a9d-8c2d-4750-a67a-07051ed8e540",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.62,
        "x": 0.19,
        "y": 0.04
      },
      "kind": "title",
      "text": "IRAKIMiD Development in MYD88 Mutant DLBCL",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a3eba42-590b-41a4-a860-a77a9dd006f6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "bec7a15a-7d61-4433-9867-eab7f73ddfad",
      "evidence": "The slide presents a clear Situation (MYD88 Mutant DLBCL), Complication (need for effective treatment), and Answer (IRAKIMiD development).",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "f2d214e9-b450-4bb0-bce2-1dfd50cb2d14",
      "evidence": "Timeline representation of clinical milestones",
      "confidence": 0.7
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}